drugset
drugset / Trial / NCT07184385

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

NCT07184385 ↗

Phase 3 Not yet recruiting 60 enrolled StemCyte, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Timeline

Start
2026-03-31
Primary completion
2027-06-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject REGENECYTE Cell therapy — —

Indications

long COVID-19 post-infectious syndrome